<DOC>
	<DOCNO>NCT00157209</DOCNO>
	<brief_summary>This prospective open label , control , randomize study test safety efficacy active specific immunotherapy tecemotide ( L-BLP25 ) treatment subject Stage IIIB Stage IV non-small cell lung cancer ( NSCLC ) . To eligible , subject enter trial demonstrate either stable disease clinical response first-line treatment ( chemotherapy alone , chemotherapy radiotherapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Following 3 week washout period , subject stratify disease status ( either Stage IIIB locoregional disease Stage IIIB malignant pleural effusion Stage IV ) , randomize either best supportive care ( BSC ) plus tecemotide ( L-BLP25 ) treatment BSC alone .</brief_summary>
	<brief_title>Phase 2b Randomized Controlled Study Tecemotide ( L-BLP25 ) Immunotherapy NSCLC ( Non-Small Cell Lung Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Stage IIIB Stage IV NSCLC Stable disease clinical response follow firstline treatment , consist either chemotherapy alone chemotherapy radiotherapy . Subjects must complete firstline treatment least 3 week prior study entry Eastern Cooperative Oncology Group ( ECOG ) performance status great equal ( &gt; = ) 2 Ability understand willingness sign write informed consent Other protocoldefined inclusion criterion could apply Received immunotherapy within 4 week prior study entry Received immunosuppressive drug within 3 week prior study entry Subjects know brain metastasis Past current history neoplasm lung carcinoma , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Autoimmune disease immunodeficiency Clinically significant hepatic , renal cardiac dysfunction Subjects clinically significant active infection Pregnant breast feed woman , woman childbearing potential , unless use effective contraception determine investigator Other protocoldefined exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>